Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates

Overview of attention for article published in Journal of Clinical Oncology, March 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 4 news outlets

twitter: 106 X users

Citations

dimensions_citation: 87 Dimensions

Readers on

mendeley: 39 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 6 news stories from 4 outlets.

De nouvelles cibles thérapeutiques représentent un besoin non satisfait en matière de translocation RCC

Nouvelles du monde, 10 Nov 2023

Rendu 3D du carcinome rénal : ©SciePro – stock.adobe.com Bien que des données récentes sur le carcinome rénal par translocation…

Treatments for Translocation RCC Require Novel Therapeutic Targets

OncLive, 10 Nov 2023

Yasser Mohamed Ali Ged, MBBS Immune checkpoint inhibitors have been associated with improved outcomes for patients with…

Targeted Therapies for Non-Clear Cell Renal Cell Carcinoma

MedPage Today, 07 Jul 2023

Meeting Coverage > ASCO Expert Roundtable: Renal Cell Carcinoma Our expert roundtable discusses practical approaches to…

Chung-Han Lee, MD, PhD, on Combination Therapy for Non-Clear Cell Kidney Cancer

MedPage Today, 17 Jun 2022

This Reading Room is a collaboration between MedPage Today® and: Cabozantinib plus nivolumab, a combination approved in 2021…

Cabozantinib/Nivolumab Showcases Clinical Benefit in Papillary Non–Clear Cell RCC

Oncology Nursing News, 13 May 2022

Encouraging objective response rates (ORRs) were observed in patients with non–clear cell renal cell carcinoma (RCC) harboring…

Cabozantinib Plus Nivolumab Shows Efficacy in Papillary Non–Clear Cell RCC

OncLive, 11 May 2022

In Partnership With: The combination of cabozantinib plus nivolumab demonstrated promising objective response rates in patients…

Michigan Publishing

Article Metrics